Aiming for Third Consecutive Gain, Tianhong CNI BIOMEDICINE ETF(159859) Rises 1.50%, Scale Hits Half-Year High

As of 14:18 on January 7, 2026, Biomedical ETF (159859) rose 1.50%, aiming for its third consecutive gain, with the latest price at 0.41 yuan. Over a longer timeframe, as of January 6, 2026, the ETF gained 3.36% over the past two weeks, ranking 1st out of 3 comparable funds. (The stocks listed above are index constituents only and do not constitute specific recommendations.)

In terms of liquidity, Biomedical ETF recorded an intraday turnover rate of 3.79% and trading volume of 133 million yuan. Over a longer period, as of January 6, its average daily trading volume reached 129 million yuan over the past week, ranking first among comparable funds.

Scale-wise, Biomedical ETF's latest AUM reached 3.461 billion yuan, hitting a half-year high and ranking 1st out of 3 comparable funds. (Data source: Wind)

In terms of shares outstanding, the ETF's share count grew 115 million units over the past two weeks, achieving significant growth and ranking 1st out of 3 comparable funds in new share increase. (Data source: Wind)

Regarding capital flows, Biomedical ETF posted a latest net capital inflow of 10.0326 million yuan. Over a longer timeframe, it saw net inflows on 6 of the past 8 trading days, totaling 38.2531 million yuan in "capital absorption," with an average daily net inflow of 4.7816 million yuan. (Data source: Wind)

Data shows leveraged funds continue to build positions. Biomedical ETF's previous day net margin purchase reached 6.0720 million yuan, with the latest margin balance at 148 million yuan. (Data source: Wind)

As of January 6, Biomedical ETF's NAV rose 14.09% over the past year, ranking 1st among comparable funds. In terms of return capability, as of January 6, 2026, since its inception, the ETF's highest monthly return was 27.87%, longest consecutive up months was 5, longest consecutive gain was 31.58%, and average return in up months was 5.62%. As of January 6, 2026, its excess return over benchmark since inception was 2.04% annualized.

On drawdowns, as of January 6, 2026, Biomedical ETF's year-to-date maximum drawdown was 0.00%, with a relative benchmark drawdown of 0.00%, the smallest among comparable funds.

In terms of fees, Biomedical ETF charges a management fee of 0.50% and a custody fee of 0.10%, the lowest among comparable funds.

Regarding tracking accuracy, as of January 6, 2026, Biomedical ETF's three-month tracking error was 0.018%, the highest tracking precision among comparable funds.

Biomedical ETF closely tracks the CNI Biomedical Index. The CNI Biomedical Index takes listed companies in the biomedical industry from the Shanghai, Shenzhen, and Beijing exchanges as its sample space, selects the top 30 securities based on comprehensive ranking of market capitalization and liquidity as index constituents, reflects the overall performance of the biomedical industry, and provides the market with index investment instruments for this segment.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.